Coffee May Lower Atrial Fibrillation Recurrence, Challenging Decades of Cardiac Caution

For decades, cardiologists have told patients with atrial fibrillation to stay away from coffee. The reasoning seemed sound: caffeine is a stimulant, the heart is already misfiring, so why add fuel to the problem? But a new randomized clinical trial published in the Journal of the American Medical Association on November 9, 2025, suggests that conventional wisdom may have been backwards all along. Patients who continued drinking coffee after electrical cardioversion—a procedure that resets an irregular heartbeat back to normal rhythm—were actually less likely to experience a recurrence of their arrhythmia than those who quit entirely.

The trial, called DECAF (Does Eliminating Coffee Avoid Fibrillation?), enrolled 200 adults across five hospitals in Australia, Canada, and the United States. All participants had persistent atrial fibrillation or atrial flutter and had just undergone successful cardioversion. Researchers then split them into two groups: one continued drinking at least one cup of caffeinated coffee daily, while the other abstained completely from coffee and other caffeine sources. Over six months, with follow-up visits at one, three, and six months, researchers tracked whether the arrhythmia came back, using wearable ECG monitors to catch any recurrences lasting 30 seconds or longer.

The results were striking. Among coffee drinkers, 47 percent experienced a recurrence of atrial fibrillation or flutter. Among those who quit coffee, the rate climbed to 64 percent. That translates to a 39 percent lower hazard of recurrence for the coffee group—a statistically significant finding with a hazard ratio of 0.61. Importantly, there was no increase in adverse events or hospitalizations between the two groups, and no deaths were reported in either arm. The baseline characteristics were balanced, with participants in both groups drinking roughly one cup of coffee per day before the trial began.

Atrial fibrillation is the most common heart rhythm disorder worldwide, affecting millions of people and expected to rise as populations age. The condition causes the heart's upper chambers to quiver chaotically rather than contract in an organized way, which can lead to heart failure, stroke, and other serious complications. For years, the assumption that caffeine triggered or worsened these arrhythmias was so entrenched that many patients were routinely counseled to avoid it. Yet emerging evidence over the past several years has chipped away at this belief. Earlier studies found that coffee consumption did not increase premature atrial contractions—the irregular heartbeats that can spark atrial fibrillation—and some observational research even suggested that moderate coffee intake was associated with a lower risk of developing the condition in the first place.

The DECAF trial is the first randomized controlled study to test this question directly, moving beyond observation to establish causation. The researchers acknowledge several limitations: the sample size was relatively small, participants knew whether they were drinking coffee or not (so there was no blinding), and adherence was self-reported rather than objectively measured. The findings also should not be stretched to cover high-dose caffeine or energy drinks, which operate in a different metabolic territory. But within those bounds, the trial provides solid evidence that moderate caffeinated coffee is safe for patients recovering from cardioversion and may actually offer protection against recurrence.

The mechanisms behind this protective effect remain unclear, though researchers have proposed several possibilities. Caffeine blocks adenosine receptors in the heart, which could have stabilizing effects on electrical conduction. Coffee also contains polyphenols and other compounds with anti-inflammatory properties, which might reduce the substrate for arrhythmias. There is also the possibility that coffee drinkers are simply more active or engaged in their recovery, though the trial did not measure this directly. What is clear is that the old caution against coffee in cardiac patients may need to be retired, at least for those with atrial fibrillation who have undergone cardioversion. The finding invites a broader reconsideration of how medical advice around caffeine has been constructed—often on the basis of plausible mechanism rather than empirical evidence—and suggests that patients and their doctors may have been overly cautious for far too long.